Member Info for biffa

HTF Abingdon can miss one of the main conditions of their £6M placing is beyond me.

Production will be in place by the end of calendar year. (they have had 6 months already)

Not much chance of our very own David Wilson getting a gong for industry this year as he has done SFA.

Commercial Director of Diagnostics, but missing in action for over a year.

@DSWilsonDx if you want to wake him up!

Pretty sure this will be on someones list.

IG margin requirement for Avacta is going down after 3pm.
Interesting to see if anyone takes advantage to buy a few more.

Incredible amount of twitter feeds and posts highlighting the Avacta 100% LFT detecting Omicron, 12 week delay on the simple desk top rubber stamp, Jim Bethell being a crook and so it goes on.

@aTomClarke is the science and tech editor at Sky who ran the piece about PCR being to slow to help with Omicron. Suggest people point him in the direction of the Avacta story and the govt incompetence in taking 3 months to rubber stamp selling them and saving lives.

My chemists in the Exeter area have rationed all LFT and that's if they have them in the first place. The latest alert went out 3 days ago to warn of shortages. That's the 3rd this month.

Received my order of AffiDX on Friday from Bioserve from an order on Tuesday which is pretty good going. It's the only way to stay safe for xmas with grand parents so spread the word.

(not interested in foot and mouth @rap)

Half yearly update this morning. MITON hold 4.66% of Avacta across various funds. Nice to see them more positive than ever.

What were the main contributors to the Trust's return over the half year?

After the substantial outperformance of quoted microcaps in the year to April 2021, the ongoing uncertainty regarding inflation led to many investors taking profits during the half year between April and October. Hence whilst Avacta was one of the better performers in the prior period, over this half year it was the greatest detractor in the portfolio, as its share price fell due to an absence of news regarding commercial orders for its novel lateral flow test for COVID-19. Another disappointing holding was Helium One, where its share price had risen just ahead of the start of the half year in anticipation of the results of its first helium wells. Whilst these confirmed the presence of helium during the half year, the geology has proved more complex than anticipated, so Helium One's share price was notably weak. A third example is Accrol, where unreliable deliveries of its toilet tissue led to its supermarket customers refusing to fund the additional manufacturing costs, at least initially. Where the prospects for imminent cash surpluses of portfolio holdings substantially diminishes, we tend to sell the positions without delay. Interestingly, in all three of the holdings outlined above, our confidence in their imminent cash prospects haven't greatly altered. Therefore, all three of these positions remain in the portfolio, and may have even greater upside potential than previously.

One step closer to our £5M a year!

Solvay Gets EPA Approval for Actizone F5 Disinfectant
30/11/2021 9:08am
Dow Jones News

Solvay (QX) (USOTC:SLVYY)
Intraday Stock Chart

Tuesday 30 November 2021

Click Here for more Solvay (QX) Charts.
By Ed Frankl


Solvay SA said Tuesday that its Actizone F5 disinfectant received approval from the U.S. Environmental Protection Agency.

The Belgium company's "ready to use" cleaning product for hard surfaces aims to reduce bacteria by disinfection against a wide range of viruses and bacteria, including SARS-CoV-2, the virus that causes Covid-19.

Solvay is now working to obtain local registrations for Actizone F5 required to market in specific states, which are expected to be completed in 2022.

This was a decent post from lst night. Muck 165, but lost in the crap.
Just in case this hasn’t already been posted, it’s a joint open letter from BIVDA and ABHI to the U.K. Health Security Agency, copying in the great and good at MRHA etc, bemoaning the CTDA process and it’s affect on smaller diagnostic businesses.

What I hadn’t seen before was the link in the letter which directs recipients to a Reuters news article about the withdrawal of tests by AVCT and NCYT.

So if the great and the good read the letter, and followed the link, they will be well aware of the effect CTDA has had on AVCT. Perhaps they did, hence why NCYT is one of the first to get approved through the process. Who knows.

https://www.ibms.org/resources/documents/abhi-bivda-ctda-letter-to-ukhsa-20211104/abhi-bivda-ctda-letter-to-ukhsa-2021.11.04.pdf

https://www.reuters.com/world/uk/two-uk-covid-test-makers-pull-devices-due-new-review-2021-11-02/

Sorry if this is old news..,!

So much for that rubbish about the list only being updated every Thursday!

If the Chairman is to be believed,next week will be 30 days from the last BOD meeting where they gave the go ahead to seek international partners for our Az antibody test. He said he had been tested the week before (and it works!) and that they had 3-4 weeks of final validation to come.
So next week we have the final product, ready to go to market.
Should be an interesting RNS.

That excel sheet is pure hi tech.
First update with 4 new tests added yesterday.

Does anyone know if that excel list of the 3 tests that passed has been updated yet?

More important question is wtf does all this take such a long time.

Nasdaq-listed PDS Biotechnology Corporation (US:PDSB:$11.80), a clinical-stage immunotherapy company developing novel cancer therapies based on its proprietary Versamune® T-cell activating technology, has temporarily suspended recruitment for a National Cancer Institute (NCI)-led Phase II clinical trial. It is evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced human papillomavirus (HPV) cancers that have progressed or returned after treatment.

NCI anticipates that the issue, which is unrelated to any safety or efficacy concerns, should be resolved timely, at which time the PDS0101 trial recruitment will resume. The timing of clinical data resulting from this trial is not expected to be impacted by the recruitment suspension. Although US investors took the news in their stride – shares in PDS are unchanged since the announcement was made – it prompted an unwarranted 20 per cent slide in Netscientific's share price back to around my entry point (‘Alpha Research: Back life sciences tech with a hefty margin of safety’, 20 July 2021). The UK group holds a 4.72 per cent stake in PDS worth £11.9m (56.5p a share), or almost three times the £4.1m cost of the investment.

Effectively, the value of the PDS shareholding and net cash of £6.7m (32p a share) post the Sofant investment backs up 90 per cent of NetScientific’s £20.6m market capitalisation. This means the group’s other holdings (‘Hunting for hidden gems’, 29 September 2021), which have a sum-of-the-parts valuation of £20m (95p a share), are in the price for a bargain basement £2m.

The valuation anomaly is glaring and presents a repeat buying opportunity worth exploiting. Buy.

Thanks to KALKAAR on advfn.
Nothing ground-breaking and certainly not focused on AZ/Proaxsis or Glycotest.. rather valuation based on sum of the parts:
-----------------

A glaring valuation anomaly exposed

A small-cap investment company's cash pile and listed holdings back up 90 per cent of its share price, meaning its unlisted portfolio is in the price for 90 per cent below carrying value

November 4, 2021
By Simon Thompson

·. Portfolio company Sofant signs contract with the UK Space Agency and European Space Agency and has successful fundraise.
· ProAxsis wins US patent for technology associated with a patented bone-specific enzyme-linked immunoassay.
NetScientific (NCSI: 98p), an investment company that backs early-stage life sciences, healthcare, and technology businesses has announced a raft of news for its portfolio companies.

Sofant, the Edinburgh University spin-out that is developing a state-of-the-art antenna for satellite communications and 5G applications, has signed a $7.3m (£5.4m) contract with the UK Space Agency and European Space Agency. It will support the commercialisation of Sofant’s low-cost, low-power satellite communications platform that requires 70 per cent less power by eliminating the need for complex and expensive cooling systems. By connecting devices wirelessly via a satellite network, Sofant’s terminal also reduces the needs for terrestrial infrastructure and makes it easier for people in rural and remote locations to access the internet. Sofant also completed a £843,000 fundraise, of which £300,000 was made by Netscientific.

ProAxsis, a health and life sciences company with a focus on respiratory diagnostics in which NetScientific holds a 95 per cent stake, has received approval of a key US patent for the technology associated with its brand-new K-POSTN Assay, which it intends to launch shortly. This is a major step towards measuring bone health with a new innovation for patients at high risk of osteoporotic fractures.

In partnership with University of Geneva, ProAxsis is creating a patented bone-specific enzyme-linked immunoassay for the detection of serum K-POSTN, a fragment produced from the digestion of periostin (a type of protein that in humans is encoded by the POSTN gene) by cathepsin K which has localised activity in bone and can predict incident fractures independently of bone marrow disease and fractured risk in post-menopausal women. The technology is likely to be of great interest to pharmaceutical companies seeking to develop new treatments for osteoporosis. That's because the K-POSTN assay can deliver specific and quantifiable outcome measurements (due to the rapid response shown by biomarkers) to both anabolic and anticatabolic drugs.

Nasdaq-listed PDS Biotechnology Corporation (US:PDSB:$11.80), a clinical-stage immunotherapy company developing novel cancer therapies based on its proprietary Versamune® T-cell activating technology, has temporarily suspended recruitment fo

Well they had no choice but to answer my 3 questions in the Q&A as i was the only one to ask anything. They might have preferred not to but had little choice.

Same type of presentation as before, but very positive on Sofant,Vortex, PDSB, ProAxis and Glycotest.

Proaxis had main board meeting last week which gave the go ahead to seek world wide partners for the anti body test, hence todays news. The product is ready to go once final testing (30 days from last week) is completed so to market by early December?

Glycotest is now back on track which is good news. Problems with lab capacity and covid interrupting sample returns.

With PDSB at $12, the SP does seem a bit of a no brainer.

Tweet and news out earlier today from ProAxis.

Reads to me that our AZ/anti body test is finished and ready to go?

ProAxsis CEO attending DxPx conference

NOVEMBER 4, 2021-POSTED BY JESSICA ROBINSON

Our CEO, Dr David Ribeiro, will be attending the DxPx Conference, taking place face-to-face in Dusseldorf and in a virtual format, November 12th – 20th 2021.

ProAxsis are actively seeking commercial partners for our portfolio of respiratory diagnostics in key territories. These include:

Laboratory-based assays for active protease biomarkers associated with chronic respiratory diseases such as cystic fibrosis, bronchiectasis and COPD.

NEATstik, a qualitative point-of-care test for active neutrophil elastase.

Our Covid-19 serology test, developed in partnership with AstraZeneca.

If your company has access to pre-existing networks of key respiratory groups, and you’d be interested in exploring any of these exciting opportunities then please contact David to request a meeting via info@proaxsis.com or the DxPx conference partnering system.

The boss is doing another proactive presentation on Thurs at 6pm.

I can't see the point unless he has some more news to promote...

Does Avacta actually have a sales or marketing side or anyone who has a clue about brand awareness etc.
Close to 8 weeks ago AS said they would target airlines, elite sports teams, events, top tier companies.
However, I have yet to see one press article linking our Avacta test to even one such outfit.
Just supply one of the prem clubs for their weekly testing, a F1 team, any airline .
Anyone have a rational answer?

Then we have this week ends rule change, which is a major shift towards LFT and we get nothing.

Hold a massive amount but just confused as to the grand plan.

Fantastic Investor Meet presentation and Q@A.

Can't even begin to list the positives as they covered so much ground.

Lots of talk going on with Fosun about the commercial roll out for Glycotest.

Proaxis on an absolute roll.

'Our stakes in the 6 other companies will be worth tens, if not hundreds of millions'

Buy some NSCI and then buy some more is the message I got.

The other impressive revelation is that we have approx 25% holdings in Pointgrab, Sagetech and Sofant when in the full year results in March no equity stake was listed.

If they can continue to get into these companies early and get meaningful holdings for minimal outlay then what's not to like.

The recent Cambridge investor hub deal looks like a bit of genius.